Stages of ovarian and endometrial cancer detection in women in the postmenapausal period in Baku city

Abstract

Aim. To study the severity (according to the stages at the time of diagnosis) of female genital cancer detected in postmenopausal women in Baku in 2016–2018.

Methods. 306 postmenopausal women with various tumors of the reproductive system were examined. The average age of the examined women was 59.3±0.4 (48–83) years. 166 (54.2%) out of 306 patients had malignant tumors of the genitalia including ovarian cancer (n=97), endometrial cancer (n=50), cervical cancer (n=13), uterine sarcoma (n=6). Clinical, functional, laboratory, radiological, and morphological studies were performed. For the analysis of the obtained digital data, discriminant analysis methods were applied. The rate (Р%) and its 95% confidence intervals (±mp%) of ovarian and endometrial cancer of the postmenopausal period among female citizens of Baku were calculated. Statistical significance of the difference between the indicators in the groups was determined by Pearson χ2-criterion. All calculations were performed in Excel 2013 and SPSS-20.

Results. According to the data of the study, ovarian cancer in the postmenopausal period was diagnosed in 15.5±3.7% of females at stage I, in 8.2±2.8% at stage II, in 66.0±4.8% at stage III, in 10.3±3.1% at stage IV of the development of the tumor process. In 68.0±6.6% of patients with endometrial cancer in the postmenopausal period, the tumor was determined at stage I, in 30.0±6.5% of patients at stage II, and in 2.0±2.0% of patients at stage III of the development of the tumor process. On comparison of the stages at detection of ovarian and endometrial cancer, a significant difference between these two forms of malignant neoplasms was found for both stages I and III.

Conclusion. Detection of genital tumors in postmenopausal women is characterized by the diagnosis of ovarian cancer mainly in the later stages of the disease (compared to endometrial cancer), which indicates the need to develop effective screening methods for earlier detection of this tumor process.

Keywords

postmenopausal period / ovarian cancer / endometrial cancer / FIGO classification / TNM system

References

[1] Aksel’ E.M. Statistics of malignant neoplasms of the female sexual sphere. Onkoginekologiya. 2012; (1): 18–22. (In Russ.)

[2] Аксель Е.М. Статистика злокачественных новообразований женской половой сферы. Онкогинекология. 2012; (1): 18–22.

[3] Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2013 году (заболеваемость и смертность). М. 2015; 250 с. [­Kaprin A.D., Starinskiy V.V., Petrova G.V. Zlokachestvennye novoobrazovaniya v Rossiiv v 2013 godu (zabolevaemost' I smertnost'). (Malignant neoplasms in Russia in 2013 (morbidity and mortality rate).) Moscow 2015; 250 p. (In Russ.)]

[4] Balogun N., Gentry-Maharaj A., Wozniak E.L., Lim A. Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentrebiobanking study. Am. J. Clin. Epidemiol. 2011; 64: 525–530. DOI: 10.1016/j.jclinepi.2010.07.008.

[5] Khatun S. Menopause and gynecological malignancy. J. South Asian Federation of Menopause Soc. 2013; 1 (2): 75–79. DOI: 10.5005/jp-journals-10032-1017.

[6] Reed N.S., Symonds R.P. Ovarian Cancer. Clin. Oncol. (R. Coll. Radiol.). 2018; 30 (8): 461–462.

[7] Kim J. Julie, Takeshi Kurita, Serdar E. Bulun progesterone action in endometrial cancer, endometriosis, ute­rine fibroids, and breast cancer. Endocr. Rev. 2013; 34 (1): ­130–162. DOI: 10.1210/er.2012-1043.

[8] Laviolette L.A., Hodgkinson K.M., Minhas N., Perez-Iratxeta C. 17β-estradiol upregulates GREB1 and accelerates ovarian tumor progression in vivo. Int. J. Cancer. 2014; 135: 1072–1084. DOI: 10.1002/ijc.28741.

[9] Son H., Khan S.M., Rahaman J. Role of FDG PET/CT in Staging of Recurrent Ovarian Cancer. Am. J. RadioGraphics. 2011; 31 (2): 569–583. DOI: 10.1148/rg.312105713.

[10] Karelina O.B., Artymuk N.V., Fetisova T.I. Ovarian cancer risk factors and possible preventive strategies. Fundamental'naya i klinicheskaya meditsina. 2018; 3 (3): 91–96. (In Russ.)

[11] Карелина О.Б., Артымук Н.В., Фетисова Т.И. Факторы риска рака яичника и возможные превентивные стратегии. Фундаментал. и клин. мед. 2018; 3 (3): 91–96.

[12] Kaprin A.D., Starinskiy V.V., Petrova G.V. Sostoyanie onkologicheskoy pomoshchi naseleniyu Rossii v 2016 godu. (Oncological care of the population in Russia in 2016.) Moscow: MNIOI im. P.A. Gertsena, filial GBU “NMIRTs” Minzdrava Rossi. 2017; 236 p. (In Russ.)

[13] Каприн А.Д., Старинский В.В., Петрова Г.В. Состояние онкологической помощи населению России в 2016 году. М.: МНИОИ им. П.А. Герцена, филиал ГБУ «НМИРЦ» Минздрава России. 2017; 236 с.

[14] Chibisova G.M., Khabarov S.V. Comprehensive definition of CA125, HE4 tumor markers and ROMA index as a predictor of ovarian cancer development. Vestnik novykh meditsinskikh tekhnologiy. 2018; 25 (3): 15–20. (In Russ.)

[15] Чибисова Г.М., Хабаров С.В. Комплексное определение онкомаркёров СА125, НЕ4 и индекса ROMA как фактор прогноза развития рака яичников. Вестн. новых мед. технол. 2018; 25 (3): 15–20.

[16] Bashmakova N.V., Roshchina M.O., Chistyakov M.A. Evaluation of histological and immunohistochemical changes in the endometrium after uterine artery embolization for uterine fibroids. Nauchno-prakticheskiy zhurnal akusherstvo i ginekologiya. 2012; (8-1): 20–24. (In Russ.)

[17] Башмакова Н.В., Рощина М.О., Чистяков М.А. Оценка гистологических и иммуногистохимических изменений в эндометрии после проведения эмболизации маточных артерий по поводу миомы матки. Науч.-практ. ж. акушерство и гинекол. 2012; (8-1): ­20–24.

[18] Urmancheeva A.F., Meshkova I.E. Questions of epidemiology and diagnosis of ovarian cancer. Prakticheskaya onkologiya. 2000; (4): 7–13 (In Russ.)

[19] Урманчеева А.Ф., Мешкова И.Е. Вопросы эпидемиологии и диагностики рака яичников. Практич. онкол. 2000; (4): 7–13.

RIGHTS & PERMISSIONS

Garashova M.A.